title: Hormonal regulation of fibrinogen synthesis in cultured hepatocytes.
abstract: Most of what was originally known of the effects of hormones on fibrinogen synthesis was based, as noted above, on experiments involving surgical removal of endocrine glands. Some caution should be exercised when using such in vivo experiments to derive the hormonal requirements of fibrinogen synthesis, however, since multiple hormonal alterations often occur in these animals. The development of a variety of ex vivo systems has allowed investigators to more carefully control the hepatocellular environment. The work of several laboratories, including our own, has now made it clear that hormones and other agents directly stimulate hepatocellular synthesis of fibrinogen. From the studies summarized here, using chick embryo hepatocytes as a model, several generalizations emerge: Fibrinogen synthesis may be considered to be a "constitutive" liver function, since hepatocytes cultured without serum, hormones or other macromolecular supplements synthesize this protein at a basal rate for several days. Addition of certain hormones (e.g. T3, dexamethasone, insulin), individually and in physiological concentrations, elicits an increase in fibrinogen production, varying with each agent in onset, dose, minimum exposure required and accompanying effects on the synthesis of other plasma proteins. Glucocorticoids and thyroid hormones are similar in the selectivity of their stimulation (neither affects albumin or transferrin synthesis) but differ in that thyroid hormones need to be present for just a short "triggering" period. The stimulation of fibrinogen synthesis by insulin occurs only following prolonged exposure to concentrations 10-times higher than the very low doses to which albumin synthesis responds rapidly.
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D001769:Blood; D002478:Cells, Cultured; D002642:Chick Embryo; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D005338:Fibrin Fibrinogen Degradation Products / Q000494:pharmacology; D005340:Fibrinogen / Q000096:biosynthesis*; D005455:Fluorescent Antibody Technique; D005938:Glucocorticoids / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology; D007375:Interleukin-1; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D011506:Proteins / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D013963:Thyroid Hormones / Q000494:pharmacology
chemical_list: D004967:Estrogens; D005338:Fibrin Fibrinogen Degradation Products; D005938:Glucocorticoids; D006728:Hormones; D007328:Insulin; D007375:Interleukin-1; D011506:Proteins; D012333:RNA, Messenger; D013963:Thyroid Hormones; C008270:leukocyte endogenous mediator; D005340:Fibrinogen; D000324:Adrenocorticotropic Hormone; D004837:Epinephrine